Key Highlights

  • Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) traded at USD 2.03, down 7.31%, in pre-market trading on Tuesday, October 27, 2026, one session after a 1-for-20 reverse stock split took effect at the open on Monday, October 26, 2026.
  • For fiscal year 2026, the company reported revenue of USD 13.43 million, down 33.87% from USD 20.31 million, and a net loss of USD 1.14 million, according to market data derived from its annual report on Form 20-F.
  • The company announced the split in its release of Wednesday, October 21, 2026 to regain compliance with the Nasdaq minimum bid price rule, after a deficiency notice of Friday, January 16, 2026 and a further grace period granted on Thursday, July 16, 2026.
  • The shares closed at USD 2.19 on Monday, October 26, 2026, up 9.50%. Pre-market prices are thinly traded and can change before the open at 9:30 a.m. ET on Tuesday, October 27, 2026.

The Pre-Market Move and Its Catalyst

Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD), an investment holding company that distributes over-the-counter pharmaceuticals and health supplements across Hong Kong and Mainland China, traded at USD 2.03 in the pre-market snapshot of Tuesday, October 27, 2026, a decline of 7.31%. That follows a close of USD 2.19 on Monday, October 26, 2026, the first session after the 1-for-20 reverse stock split, which the company announced in its release of Wednesday, October 21, 2026. The decline appears consistent with a partial give-back of the first-day gain, a pattern that often follows reverse splits in low-priced shares. No further company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the move.

How the Latest Results Frame the Move

The reverse split exchanged 20 existing shares for one, raised the par value from USD 0.001 to USD 0.02 per share, assigned the new CUSIP identifier G6365B112 and rounded fractional shares up to the next whole share. The company stated that the split is primarily intended to help it regain compliance with the Nasdaq minimum bid price requirement for the Nasdaq Capital Market, and that there is no assurance it will do so. Fiscal year 2026 revenue was USD 13.43 million, down 33.87%, with a net loss of USD 1.14 million. The decline in revenue matters because a smaller business gives less support to a higher nominal share price. Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) also holds a USD 200 million mixed securities shelf registration, which would allow future share issuance.

Risks and What to Watch

The bull reading rests on the compliance pathway: a closing bid of at least USD 1.00 for ten consecutive business days would normally satisfy the rule, and the post-split price of USD 2.03 to USD 2.19 leaves a margin of more than 100%. The bear reading rests on the shrinking revenue base and the shelf registration, because reverse splits do not alter the underlying value of a company. Named risks are dilution through the shelf, a repeat of bid price non-compliance if the shares drift lower, and thin liquidity, since 20 former shares became one. Investors should watch the Nasdaq confirmation of compliance, the next periodic filing of results, any use of the shelf registration and the Federal Reserve decision on Wednesday, October 28, 2026.

Where Things Stand

The answer is that Cellyan Biotechnology Co., Ltd (NASDAQ:HKPD) has so far held most of the price level created by its reverse split, and the pre-market decline of 7.31% appears consistent with a partial reversal of the first-day gain of 9.50%. The key number is USD 13.43 million of fiscal year 2026 revenue, down 33.87%. The next catalysts are the Nasdaq compliance confirmation, the next periodic results, any use of the shelf registration and the Federal Reserve decision on Wednesday, October 28, 2026. Pre-market prices are snapshots and can change before the open, and this is not investment advice.